TrueCAGR

Max Healthcare Institute Limited

NSE: MAXHEALTHBSE: 543220ISIN INE027H01010Face value ₹10consolidated
₹1,080
+3.98% · 2026-11-20 · 52-wk ₹813–₹1,181
Source: BSE filings · Financials to FY2026 · 5 years of history · Data last updated: results filed 30 Oct 2026, prices to 20 Nov 2026 · How we calculate thisconsolidatedstandalone
Section 02 · Synthesis

What stands out?

The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.

StrengthConcernWatchContext
StrengthTalking point

Profit outpacing revenue

Profit grew 34.1% while revenue grew 19.1%, so the company kept more of each rupee of revenue as profit.

Net profit growth+34.1%Revenue growth+19.1%

Importance 63 / 95 · growth

StrengthTalking point

Compounding revenue

Revenue compounded at 20.8% a year over 4 years (₹3,931 → ₹8,373).

Importance 59 / 95 · growth

StrengthTalking point

Book value compounding

Net worth compounded at 14.4% a year over 4 years (₹6,282 → ₹10,747).

Importance 54 / 95 · financial health

Section 03 · The company

Who is this company?

Classified by the exchange under Healthcare › Healthcare › Healthcare Services › Hospital.

Market cap
₹1.05 L cr
FY2026 revenue
₹8,373 cr
FY2026 net profit
₹1,442 cr
Net worth
₹10,747 cr
Total debt
₹3,478 cr
EPS (basic)
₹14.83
Listed
NSE · BSE
Reporting
Ind-ASApr–Mar

Peer set used on this page: 3 hospital.

Section 04 · Business performance

Is the business growing?

Revenue grew 20.8% a year over 4 years, from ₹3,931 cr in FY2022 to ₹8,373 cr in FY2026. Net profit grew 24.3% a year over the same period.

Revenue & net profit — FY22 to FY26₹ crore · consolidated
₹'000 cr02579012REVENUENET PROFIT4k605FY225k1,104FY235k1,058FY247k1,076FY258k1,442FY26
RevenueNet profit
Strength

Profit grew 34.1% while revenue grew 19.1%, so the company kept more of each rupee of revenue as profit.

Rule PROFIT_FASTER_THAN_REVENUE

Revenue growth per year
+20.8%over 4 years (FY22–FY26)
Revenue growth
+19.1%vs last year
Net profit growth
+34.1%vs last year
Change in net profit since FY22
+138%

Revenue compounded at 20.8% a year over 4 years (₹3,931 → ₹8,373).

Net profit grew 34.1% year on year (FY2025 → FY2026).

Revenue grew 19.1% year on year (FY2025 → FY2026).

Section 05 · Recent activity

What changed recently?

In Q2 FY27 (Jul–Sep 2026), revenue was ₹2,569 cr (up 20.3% on the same quarter last year) and net profit ₹414 cr (down 15.6%).

Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.

Watch

Q2 FY27 net profit declined 15.6% while revenue grew 20.3% vs the same quarter last year — a gap of 36.0 percentage points.

Rule QTR_PROFIT_VS_REVENUE_GROWTH

Strength

Q2 FY27 revenue was ₹2,569 cr, up 20.3% from ₹2,135 cr in Q2 FY26 a year earlier.

Rule QTR_REVENUE_GROWTH_YOY

Concern

Q2 FY27 net profit was ₹414 cr, down 15.6% from ₹491 cr a year earlier.

Rule QTR_PROFIT_GROWTH_YOY

A. Quarterly results

Latest quarters — Q3 '25 to Q2 '27₹ crore · consolidated
₹'000 cr01223001REVENUENET PROFIT2k239Q3 '252k319Q4 '252k308Q1 '262k491Q2 '262k301Q3 '262k342Q4 '262k323Q1 '273k414Q2 '27
RevenueNet profit
QuarterRevenueYoYNet profitYoYNet margin
Q3 FY251,868+40.0%239−17.5%12.8%
Q4 FY251,910+34.2%319+26.8%16.7%
Q1 FY262,028+31.4%308+30.3%15.2%
Q2 FY262,135+25.1%491+74.3%23.0%
Q3 FY262,068+10.7%301+26.0%14.6%
Q4 FY262,143+12.2%342+7.3%16.0%
Q1 FY272,366+16.7%323+4.9%13.6%
Q2 FY272,569+20.3%414−15.6%16.1%

B. TTM snapshot

Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters

Revenue
₹9,146 crTTM
EBITDA
₹2,629 crTTM
EBIT
₹2,126 crTTM
PBT
₹1,806 crTTM
Net profit
₹1,381 crTTM

C. Corporate actions

3 Jul 2026DividendFinal Dividend - Rs. - 2.0000 — ₹2.00/share
4 Jul 2025DividendFinal Dividend - Rs. - 1.5000 — ₹1.50/share
23 Aug 2024DividendFinal Dividend - Rs. - 1.5000 — ₹1.50/share
8 Sept 2023DividendFinal Dividend - Rs. - 1.0000 — ₹1.00/share
Section 06 · Business performance

Is it becoming more profitable?

EBITDA margin was 28.7% in FY2026, against 27.2% in FY2022. ROE was 14.3% and ROCE 14.7% in FY2026.

Margins — FY22 to FY26% of revenue · consolidated
0%5%10%15%20%25%30%35%28.7%16.9%FY22FY23FY24FY25FY26
EBITDA marginNet margin
Strength

ROE improved from 12.1% to 14.3% year on year.

Rule ROE_IMPROVED_YOY

EBITDA margin now
28.7%
5-year range
27.2–30.9%
ROE FY2026
14.3%
ROCE FY2026
14.7%
Section 07 · Financial health

Is financial health improving?

Debt-to-equity was 0.32x in FY2026, against 0.12x in FY2022; interest coverage 8.33x. Operating cash flow was 1.13x net profit.

Net worth — FY22 to FY26₹ crore · consolidated
₹'000 cr0713206kFY227kFY238kFY249kFY2511kFY26
Net worth (shareholders' funds)
Strength

Net worth compounded at 14.4% a year over 4 years (₹6,282 → ₹10,747).

Rule NET_WORTH_COMPOUNDING

Operating cash flow vs net profit₹ crore · FY22–FY26
0k1k1k2k748605FY221k1kFY231k1kFY241k1kFY252k1kFY26
Operating cash flowNet profit
Total debt
₹3,478 cr
Operating cash flow ÷ net profit
1.13×FY2026
Free cash flow
₹165 cr
Current ratio
0.89×

Operating cash flow has matched or exceeded reported profit in 5 of the last 5 profit-making years (latest 1.13×).

Free cash flow has been positive in 5 of the last 5 years.

Section 08 · Relative position

How does it compare with peers?

Within its 3-company Hospital peer group, it ranks 2 of 3 on return on equity and 1 of 3 on EBITDA margin. Its P/E of 76.1 compares with a peer median of 58.7.

Ranked against 3 hospital (FY2026, consolidated). No peer-relative rule fired for this company.

Revenue growth

MAXHEALTH · 1st of 3 · set median 17.3%

MAXHEALTH19.1%FORTIS17.3%APOLLOHOSP15.8%

EBITDA margin

MAXHEALTH · 1st of 3 · set median 23.4%

MAXHEALTH28.7%FORTIS23.4%APOLLOHOSP15.7%

Return on equity

MAXHEALTH · 2nd of 3 · set median 14.3%

APOLLOHOSP21.5%MAXHEALTH14.3%FORTIS11.0%

P/E ratio

MAXHEALTH · 3rd of 3 · set median 58.7×

APOLLOHOSP56.5×FORTIS58.7×MAXHEALTH76.1×
P / E
76.1×TTM to Sept 26
P / B
9.8×latest book
P / S
11.5×TTM sales
Earnings yield
1.3%TTM to Sept 26

On the trailing twelve months. Last full year: P/E 72.8× · P/S 12.3× · ROE 14.3%.

Section 09 · The stock

How has the stock performed?

The share price is down 7.6% over 1 year, up 78.7% over 3 years (21.3% a year) and up 202% over 5 years (24.7% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 8.6% below its 52-week high.

Adjusted close — 2020-09 to 2026-11₹ per share · split / bonus adjusted
0k₹1,0802020202120222023202420252026
Context

Over 4 years profit (24.3% a year) and the stock (21.3% a year) compounded at roughly the same rate — but FY2022 profit (₹605) was well below the through-cycle level (~₹1,076), so this rate is inflated by the recovery from a low base.

Rule STOCK_TRACKED_EARNINGS · recovery

Business vs stock — 5-year compound annual rate
Net profit24.3%/yrShare price21.3%/yr
1-year return
−7.6%
3-year return
+78.7%
5-year return
+202.1%
From 52-wk high
−8.6%
Section 10 · Technical data

What does the technical data say?

Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.

vs 50-day avg
Above₹942
vs 200-day avg
Above₹1,011
RSI (14)
79.2overbought
MACD histogram
21.3
From 52-wk high
−8.6%
From 52-wk low
+32.7%
30-day volatility
31.8%ann.
6-month return
+2.8%
RSI (14) · 0–10079.2 — overbought
0305070100OVERSOLDOVERBOUGHT79.2
Section 11 · Open questions

What should I investigate further?

Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.

  • Watch
    Unusual tax rate
    Effective tax rate of 13.9% (FY2026) is well below the ~25% corporate norm — a one-off tax item may be flattering or depressing reported profit.
    EFFECTIVE_TAX_UNUSUAL · conviction 37
Data coverage is complete — 5 years of financials (FY2022–FY2026), full P&L, balance sheet and cash-flow statement, sector metrics fully mapped.
Section 12 · Reference

The numbers

The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.

Income & balance sheet — ₹ crore, consolidated
MetricFY22FY23FY24FY25FY26
Revenue3,9314,5635,4067,0288,373
Total income4,0594,7025,5847,1848,536
EBITDA1,0701,3801,6702,0042,405
Profit before tax7391,0641,3651,4061,676
Net profit6051,1041,0581,0761,442
EPS (₹)6.311.410.911.114.8
Net worth6,2827,4108,4089,38110,747
Total debt7276891,2993,0103,478
Operating cash flow7481,2091,1221,4601,633
Free cash flow192877349494165
Key ratios — consolidated
RatioFY22FY23FY24FY25FY26
Growth
Revenue growth YoY—16.118.530.019.1
Profit growth YoY—82.4-4.21.734.1
Profitability
EBITDA margin %27.230.230.928.528.7
Net margin %14.923.518.915.016.9
Return on equity %9.616.113.412.114.3
Return on capital %12.115.216.014.914.7
Leverage & cash
Debt to equity0.120.090.150.320.32
Cash flow ÷ profit1.241.101.061.361.13
Current ratio1.321.861.370.880.89
Financials: BSE Integrated Filing inline XBRL (SEBI taxonomy), normalised to standard metric keys. Prices: end-of-day — history loaded from NSE end-of-day files, new days from the BSE bhavcopy; raw OHLC preserved; a corporate-action factor produces the adjusted series. The insight engine writes factual observations from fixed rules — it does not make recommendations. Not investment advice.